Vivici Raises €12.5M for Animal-Free Dairy Protein Production

The burgeoning field of alternative proteins is gaining significant momentum as Dutch innovator Vivici announces a substantial €12.5 million funding injection from the European Innovation Council (EIC) Accelerator Programme. This strategic capital infusion is earmarked to accelerate the commercialization and market penetration of Vivici's proprietary animal-free dairy proteins, produced via precision fermentation. The funding follows a robust Series A round earlier this year, which saw Vivici secure €32.5 million from prominent investors including APG on behalf of ABP and Invest-NL.

Vivici, established in 2023, is at the forefront of leveraging cutting-edge biotechnology to replicate the functionality and nutritional profile of traditional dairy proteins without animal involvement. Their core technology, precision fermentation, utilizes microorganisms to produce specific proteins, offering a sustainable and scalable solution to meet the escalating global demand for protein. This approach sidesteps the environmental and ethical concerns associated with conventional dairy farming, positioning Vivici as a key player in the future of food ingredients.

The newly secured EIC funding will be instrumental in scaling production capabilities and expanding the market reach for Vivici's flagship product line, branded as Vivitein™. This portfolio includes functional protein ingredients designed to empower food manufacturers to develop premium products that align with evolving consumer preferences for health, sustainability, and ethical sourcing. The company has already made significant strides, launching Vivitein™ BLG (beta-lactoglobulin) and recently introducing Vivitein™ LF (lactoferrin) to the U.S. market, both achieving self-affirmed GRAS status.

Stephan van Sint Fiet, CEO of Vivici, expressed enthusiasm for the EIC's backing, stating, "Securing the support of the EIC is a powerful endorsement of what we are building at Vivici. It tells us that Europe sees the same opportunity we do, to turn the promise of precision fermentation into a commercial reality, at scale, for the benefit of customers and consumers. This funding allows us to move faster on exactly that." This sentiment underscores the strategic importance of the EIC's role in fostering deep-tech innovation across the European Union.

The precision fermentation market is projected for significant growth, driven by increasing consumer awareness and regulatory support for sustainable food technologies. Industry analysts predict the global alternative protein market to reach hundreds of billions of dollars in the coming decade. Vivici's success in attracting substantial funding from both private investors and a key EU innovation body highlights the immense potential and investor confidence in this sector. The company's ability to deliver high-quality, animal-free dairy proteins at scale is crucial for its long-term success and its contribution to a more sustainable food system.

Simon Penfold, Chief Commercial Officer at Vivici, emphasized the market's readiness for their offerings: "Customer demand for our ingredients is already strong, and this backing lets us meet it with the supply and pace the market expects." The EIC Accelerator Programme, known for its rigorous selection process, supports groundbreaking innovations with blended finance, combining grants and equity to bridge the crucial gap between technological validation and market scalability. Vivici's selection among 38 innovative companies signifies the transformative potential of their technology.